Leukemia cell lines: In vitro models for the study of acute promyelocytic leukemia

1995 ◽  
Vol 19 (10) ◽  
pp. 681-691 ◽  
Author(s):  
H.G. Drexler ◽  
H. Quentmeier ◽  
R.A.F. MacLeod ◽  
C.C. Uphoff ◽  
Z.-B. Hu
Virology ◽  
1980 ◽  
Vol 105 (2) ◽  
pp. 425-435 ◽  
Author(s):  
Joel S. Greenberger ◽  
Robert J. Eckner ◽  
Wolfram Ostertag ◽  
Giulia Colletta ◽  
Sandra Boschetti ◽  
...  

2020 ◽  
Vol 11 (1) ◽  
pp. 7445-7452

Acute promyelocytic leukemia is the most prevalent AML malignancy. The side effects caused by chemotherapeutic drugs have primarily led to the increased use of natural products for cancer treatment. Gaillardin, a medicinal herb, has been reported to have anti-proliferative effects on various cancer cells. In this study, cytotoxic and apoptotic effects of Gaillardin were investigated on acute promyelocytic leukemia cell lines, NB4. Different concentrations of Gaillardin were used to treat NB4 cells for 48 and 72 hours. Then cell viability was assessed using MTT assay. Flow cytometry was applied to the assessment of apoptosis by using Annexin V and Propidium iodide staining method. In order to determine the expression levels of Bax and Bcl-2, RT-PCR was carried out. Statistical data analysis was done by ANOVA (one-way). MTT assay results showed that Gaillardin concentrations of 7, 8, and 9 µM would significantly reduce the percentage of live cells (P< 0.001)c. Flow cytometry results showed that Gaillardin significantly increased apoptotic cell percentage in comparison with the control groups (p< 0.05). Gaillardin can be considered as a candidate for further studies on the methods for treating various cancer types.


2021 ◽  
Vol 28 (3) ◽  
pp. 1790-1794
Author(s):  
Hans G. Drexler ◽  
Stefan Nagel ◽  
Hilmar Quentmeier

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that is genetically characterized by the absence of both the Philadelphia chromosome and BCR-ABL1 fusion gene and the high prevalence of mutations in the colony-stimulating factor 3 receptor (CSF3R). Additional disease-modifying mutations have been recognized in CNL samples, portraying a distinct mutational landscape. Despite the growing knowledge base on genomic aberrations, further progress could be gained from the availability of representative models of CNL. To address this gap, we screened a large panel of available leukemia cell lines, followed by a detailed mutational investigation with focus on the CNL-associated candidate driver genes. The sister cell lines CNLBC-1 and MOLM-20 were derived from a patient with CNL and carry CNL-typical molecular hallmarks, namely mutations in several genes, such as CSF3R, ASXL1, EZH2, NRAS, and SETBP1. The use of these validated and comprehensively characterized models will benefit the understanding of the pathobiology of CNL and help inform therapeutic strategies.


Sign in / Sign up

Export Citation Format

Share Document